

STEINMETZ MICHAEL  
Form 3  
August 02, 2012

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL  
OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |  |  |
|---|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person *               |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol                               |  |
| Â Clarus Lifesciences I, L.P.                           |         | (Month/Day/Year)                     | GLOBUS MEDICAL INC [GMED]  |  |
| (Last)  | (First) | (Middle)                             | 08/02/2012   |  |
| C/O CLARUS VENTURES, LLC, Â 101 MAIN STREET, SUITE 1210 |         |                                      | 4. Relationship of Reporting Person(s) to Issuer                                 | 5. If Amendment, Date Original Filed(Month/Day/Year) |
| (Street)  |         |                                      | (Check all applicable)   |  |
| CAMBRIDGE, Â MA Â 02142                                 |         |                                      | <input type="checkbox"/> Director  | <input checked="" type="checkbox"/> 10% Owner        |
| (City)  | (State) | (Zip)                                | <input type="checkbox"/> Officer   | <input type="checkbox"/> Other                       |
|   |         |                                      | (give title below)   | (specify below)                                      |
|   |         |                                      | 6. Individual or Joint/Group Filing(Check Applicable Line)                       |  |
|   |         |                                      | <input type="checkbox"/> Form filed by One Reporting Person                      |  |
|   |         |                                      | <input checked="" type="checkbox"/> Form filed by More than One Reporting Person |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form:<br>Direct (D)<br>or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|------------------------------------|--|---|--|
| Class A Common Stock               | 604,265  | I   | By Fund <sup>(1)</sup>                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and Expiration Date<br>(Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|---|---|--|---|---|--|
|---|---|--|---|---|--|

Edgar Filing: STEINMETZ MICHAEL - Form 3

|                                     | Date Exercisable | Expiration Date | Title                | Amount or Number of Shares | Security      | Direct (D) or Indirect (I) (Instr. 5) |                    |
|-------------------------------------|------------------|-----------------|----------------------|----------------------------|---------------|---------------------------------------|--------------------|
| Series E Preferred Stock <u>(2)</u> | 07/23/2007       | ∧ <u>(2)</u>    | Class A Common Stock | 7,444,168 <u>(2)</u>       | \$ <u>(2)</u> | I                                     | By Fund <u>(1)</u> |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |                             |
|--|---------------|-----------|---------|-----------------------------|
|  | Director      | 10% Owner | Officer | Other                       |
| Clarus Lifesciences I, L.P.<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142        | ∧             | ∧ X       | ∧       | ∧                           |
| Simon Nicholas<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                     | ∧             | ∧         | ∧       | Managing dir. of GP         |
| GALAKATOS NICHOLAS<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                 | ∧             | ∧         | ∧       | Managing dir. of GP         |
| LIPTAK ROBERT<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                      | ∧             | ∧         | ∧       | Managing dir. of GP         |
| WHEELER KURT<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                       | ∧             | ∧         | ∧       | Managing dir. of GP         |
| STEINMETZ MICHAEL<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                  | ∧             | ∧         | ∧       | Managing dir. of GP         |
| HENNER DENNIS<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                      | ∧             | ∧         | ∧       | Managing dir. of GP         |
| Clarus Ventures I Management, L.P.<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142 | ∧             | ∧         | ∧       | General Partner             |
|  | ∧             | ∧         | ∧       | GP Clarus Ventures I Mngmt. |

Clarus Ventures I, LLC  
 C/O CLARUS VENTURES, LLC  
 101 MAIN STREET, SUITE 1210  
 CAMBRIDGE, MA 02142

## Signatures

|   |            |
|---|------------|
| /s/ Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P., general partner of Clarus Lifesciences I, L.P. | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, as attorney-in-fact for Nicholas Simon   | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, as attorney-in-fact for Nicholas Galakatos   | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak   | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, as attorney-in-fact for Kurt Wheeler   | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, as attorney-in-fact for Michael Steinmetz  | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, as attorney-in-fact for Dennis Henner  | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P.   | 08/02/2012 |
| __Signature of Reporting Person   | Date       |
| Robert Liptak, Managing director of Clarus Ventures I, LLC  | 08/02/2012 |
| __Signature of Reporting Person   | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).  
 Clarus Ventures I Management, L.P. ("Clarus I Management") as the sole general partner of Clarus Lifesciences I, L.P. (the "Fund") and Clarus Ventures I, LLC ("Clarus I GPLLC") as the sole general partner of Clarus I Management, may be deemed to beneficially own certain of the shares held of record by the Fund. Clarus I Management disclaims beneficial ownership of all shares held of record by the Fund.  
 (1) Fund in which Clarus I Management does not have an actual pecuniary interest. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of Clarus I GPLLC, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Clarus I GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by the Fund in which he does not have an actual pecuniary interest.  
 The Series E Preferred Stock is convertible into the Company's Class A Common Stock, currently on a one-for-one basis, and will  
 (2) automatically convert into Class A Common Stock upon the closing of the Company's initial public offering. The Series E Preferred Stock has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.